ATE403678T1 - Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon - Google Patents

Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon

Info

Publication number
ATE403678T1
ATE403678T1 AT99968197T AT99968197T ATE403678T1 AT E403678 T1 ATE403678 T1 AT E403678T1 AT 99968197 T AT99968197 T AT 99968197T AT 99968197 T AT99968197 T AT 99968197T AT E403678 T1 ATE403678 T1 AT E403678T1
Authority
AT
Austria
Prior art keywords
pth
derivatives
functional
linker molecule
peptides consisting
Prior art date
Application number
AT99968197T
Other languages
English (en)
Inventor
Thomas Gardella
Henry M Kronenberg
John T Potts Jr
Harald Jueppner
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE403678T1 publication Critical patent/ATE403678T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/635Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99968197T 1998-12-31 1999-12-30 Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon ATE403678T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11457798P 1998-12-31 1998-12-31

Publications (1)

Publication Number Publication Date
ATE403678T1 true ATE403678T1 (de) 2008-08-15

Family

ID=22356116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968197T ATE403678T1 (de) 1998-12-31 1999-12-30 Peptide, bestehend aus zwei funktionellen pth- domänen, die durch ein linkermolekül verknüpft sind, und derivate davon

Country Status (7)

Country Link
US (1) US20080058505A1 (de)
EP (1) EP1147133B1 (de)
JP (1) JP2002533115A (de)
AT (1) ATE403678T1 (de)
AU (1) AU2486800A (de)
DE (1) DE69939275D1 (de)
WO (1) WO2000039278A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942035D1 (de) 1998-11-25 2010-04-01 Gen Hospital Corp Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
ES2251793T3 (es) 1998-12-31 2006-05-01 The General Hospital Corporation Receptor pth y ensayo de seleccion utilizando el mismo.
CA2416224C (en) * 2000-07-10 2015-08-25 Edwin W. Ades Multiple antigenic peptides immunogenic against streptococcus pneumoniae
CA2454275C (en) 2001-07-23 2012-10-23 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
ATE401345T1 (de) * 2002-08-06 2008-08-15 Aplagen Gmbh Synthetische mimetika von physiologischen bindungsmolekülen
US8088734B2 (en) * 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
AU2008282805B2 (en) 2007-08-01 2014-05-01 Chugai Pharmaceutical Co., Ltd. Screening methods using G-protein coupled receptors and related compositions
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
RU2604809C2 (ru) 2010-05-13 2016-12-10 Дзе Дженерал Хоспитал Корпорейшн Аналоги паратиреоидного гормона и их применение
JP2014521594A (ja) * 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
US20200354428A9 (en) * 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US5527772A (en) * 1987-10-20 1996-06-18 Holick; Michael F. Regulation of cell proliferation and differentiation using peptides
US5434246A (en) * 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
US5556940A (en) * 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2000023594A1 (en) * 1998-10-22 2000-04-27 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
DE69942035D1 (de) * 1998-11-25 2010-04-01 Gen Hospital Corp Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
AU1918300A (en) * 1998-11-25 2000-06-13 General Hospital Corporation, The Amino-terminal modified parathyroid hormone (pth) analogs
WO2000032771A1 (en) * 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof

Also Published As

Publication number Publication date
EP1147133B1 (de) 2008-08-06
WO2000039278A8 (en) 2001-01-11
AU2486800A (en) 2000-07-31
DE69939275D1 (de) 2008-09-18
JP2002533115A (ja) 2002-10-08
US20080058505A1 (en) 2008-03-06
EP1147133A4 (de) 2003-02-12
EP1147133A2 (de) 2001-10-24
WO2000039278A2 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
DE69939275D1 (de) Peptide, bestehend aus zwei funktionellen PTH-Domänen, die durch ein Linkermolekül verknüpft sind, und Derivate davon
BRPI0407071B8 (pt) peptídeo purificado, seu método de produção e composição farmacêutica para o tratamento de distúrbios gastrointestinais
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
CA2395699A1 (en) NUCLEIC ACIDS, PROTEINS AND ANTIBODIES
WO2002057303A3 (en) Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
BR9812096A (pt) Proteìna receptora/ligante solúvel interleucina-6 quimérica, seus análogos e seus usos
CY1107881T1 (el) Τροποποιημενα πεπτιδια ως θεραπευτικοι παραγοντες
DE60230046D1 (de) Peptide, die atherosklerotische schädigungen binden
HRP20090324T1 (hr) Moduliranje interakcije između hgf beta lanca i c-met
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
DE602005019495D1 (de) Ligand für den Formylpeptidrezeptorähnlichen- 2 (FPRL2) G Protein gekoppelten Rezeptor und dessen Anwendung
NO20053986L (no) Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1.
ATE360643T1 (de) Humanes cyr61
PE20010516A1 (es) Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina
Volz et al. Molecular characterization of metal-binding polypeptide domains by electrospray ionization mass spectrometry and metal chelate affinity chromatography
PL377506A1 (pl) Przeciwciało (11C7) anty Nogo oraz jego zastosowanie farmaceutyczne
WO2002026930A3 (en) Nucleic acids, proteins, and antibodies
Heck Vancomycin in vacuo
Cardona et al. Synthesis of cyclic peptides from unprotected precursors using removable Nα‐(1‐(4‐methoxyphenyl)‐2‐mercaptoethyl) auxiliary
Pillai et al. A flexible method for preparation of peptide homo‐and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups
Muttenthaler et al. p‐Nitrobenzyl protection for cysteine and selenocysteine: A more stable alternative to the acetamidomethyl group
Decalf et al. A novel method to produce synthetic murine CXCL10 for efficient screening of functional variants
Koglin et al. Novel modified and radiolabelled neuropeptide Y analogues to study Y-receptor subtypes
ATE368750T1 (de) Screening-verfahren zum identifizieren von g- proteinen und anderen verbindungen,die die phosphodiesterase (pde)-aktivität beeinflussen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties